Loading in 5 sec....

Equivalence and Bioequivalence: Frequentist and Bayesian views on sample sizePowerPoint Presentation

Equivalence and Bioequivalence: Frequentist and Bayesian views on sample size

Download Presentation

Equivalence and Bioequivalence: Frequentist and Bayesian views on sample size

Loading in 2 Seconds...

- 78 Views
- Uploaded on
- Presentation posted in: General

Equivalence and Bioequivalence: Frequentist and Bayesian views on sample size

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Equivalence and Bioequivalence:Frequentist and Bayesian views on sample size

Mike Campbell

ScHARR

CHEBS FOCUS fortnight 1/04/03

- Many trials are not designed to prove differences but equivalences
Examples : generic drug vs established drug

Video vs psychiatrist

NHS Direct vs GP

Costs of two treatments

Alternatively – non-inferiority (one-sided)

- For some trials (e.g. of generics) one would like to show similar efficacy at less cost
- Thus can have an equivalence and a cost difference trial in one study

- AHEAD (Health Economics And Depression)
- Trial of trycyclics, SSRIs and lofepramine
- Clinical outcome - depression free months
- Economic outcome – cost
- Powered to show equivalence to within 5% with 90% power and 5% significance (estimated effect size 0.3 and SD 1.0)

- For bio-equivalence we are trying to show that two therapies have same action
- Usually compare serum profiles by e.g. AUC
- Often paired studies
- FDA: 80:20 rule 80% power to detect 20% difference

- Impossible to prove null hypothesis
- All we can do is show that differences are at most Δ
- Choose Δ to be a difference within which treatments deemed equivalent
- General approach – perform two one-sided significance tests of
H0: μ1-μ2> Δ and μ1-μ2< -Δ

If both are significant, then can conclude equivalence

Figure from Jones et al (BMJ 1996) showing relationship

between equivalence and confidence intervals

Assume sd s is known.

Then 100(1-a)% CI to compare difference in means is

where

Treatments deemed equivalent if interval falls in

-Δ to +Δ

Let τ = μA - μB

Let η = Δ - zα/2 σλ

(1)

Maximal Type I error rate is (1) when τ=Δ

Power is defined when (1) has τ=0

or

If treatment groups have same size, n,

then required sample size is

(2)

- This is similar to testing for a difference
- Except
- Usually Δ is smaller than for a difference trial
- We use β/2 rather than β

- Poor trials (e.g. poor compliance and larger measurement errors bias trial towards null)
- Jones et al (1996) suggest using an ITT approach and ‘per-protocol’ and hope they give similar results!

- Analysis objective Outcome is positive if the data obtained are such that there is a posterior probability of at least ω that τ >0
- Design objective We require the sample size (n1,n2)be large enough so there is a probability of at least ψ of obtaining a positive result.
The probability ψ is known as the assurance

- Let prior expectation of (μ1,μ2)T be ma according to analysis prior and md according to the design prior
- Let variances be Va and Vd for analysis and design priors respectively
- Let be ( )T,the observed data
- Let S be the sampling variance matrix (note this depends on n1 and n2)

Let Wa =Va-1 ,Ws=S-1 and V*=(Wa+Ws)-1 and a=(1,-1)T

Under analysis prior

Posterior mean of (μ1, μ2) is Normally distributed with expectation and variance

Unconditional distribution of is Normal with mean and variance

From which can get sample size calculation

(See O Hagan and Stevens)

If

then the Bayesian methods for determining sample size agree with frequentist

If

Va-1 =0 – weak analysis prior –’vague’ prior

If

- strong design prior

Vd=0

- Analysis objective: Outcome of study is positive if the upper limit of the (1-ω)% prediction interval for τ is < Δ (one sided) or upper and lower limits of prediction interval for τ are within ± Δ (two sided).
- Design objective: Sample size is such that there is a probability of at least ψ of obtaining a positive result.

A modification of O’Hagan and Stevens suggests that for equivalence trials, a positive outcome occurs when

Two-sided and

One-sided

Sample size also a modification of O’Hagan and Stevens

ma - the analysis prior mean could be 0

md - the design prior mean could be 0

Then we have some information about the possible differences,

so ‘proving’ the null hypothesis is difficult

E.g. if we were 50% sure that δ>0, before the trial

then cannot be 80% sure that δ=0 after the trial

CIs will be shifted towards ma

If ma=0, then probability of a positive event increased

95% CIs will be narrower than for the frequentist approach

- Bayesian approach more natural for equivalence (Can prove H0)
- More work on getting pragmatic suggestions for Va and Vd needed